Endocrine Abstracts

One of the most frequent complications of diabetes is diabetic sensorimotor peripheral polyneuropathy (DSPN). B vitamins successfully used for the treatment DSPN. However, prolonged use of vitamins B6 and B12 in effective doses limited by the comorbidities and possibility of the neurotoxic reactions development, as for vitamin B1, its low bioavailability of water-soluble forms. This determines whether the use of fat-soluble form of benfotiamine with maximum bioavailability.

Goal: To evaluate the efficacy of using benfotiamine monotherapy (Milgamma mono) in the stabilization of DSPN after achieving therapeutic result.

Materials and methods: The study included 34 patients with DSPN. All patients obtained Milgamma injections N5 and then Milgamma dragees (three tablets per day) for a month. After washout period, the patients were divided into two groups: Group 1 - stopped treatment after achieving a therapeutic effect (n=21), Group 2 - continue treatment with Milgamma mono 300 per day for 2 months (n=13). Rating pain in legs conducted by visual analog scale (VAS), and the severity of DSPN rated on standard scales NSS, TSS, NDS and electromyography (EMG).

Results and discussion: The significant positive trend in all performance indicators were registered after washout period in all patients included in the trial. After randomization into groups and by the end of treatment in Group 2 there was a significant positive trend compared to Group 1 and the initial result. VAS day decreased to 0.5±0.97 (P<0.05), and at night 0 (P<0.05). By scale TSS to 0.1±0.32 (P<0.05), on a scale of NSS to 0.2±0.63 (P<0.05), by NDS scale total score to 5.1±2.96 (P<0.05).

According to the results EMG marked improvement M-response amplitude (mV): n.peroneus (right 4.13±2.23, left 5.18±4.61) and n.tibialis (right 7.4±4.36; left 8±3.86 (P<0.05)), the speed of nerve impulse increased (m\s): n.peroneus ((right 67.4±11.7; left 64.9±13)) (P<0.05), n.tibialis (right 52.6±14.7 (P<0.05); left 44.8±18.9), in Group 2.

Conclusions: i) The using injectable form of Milgamma then assigning Milgamma pills leads to the improvement of both subjective and objective criteria DSPN, but the effect of treatment is not preserved after its termination within 2 months of observation. ii) The using Milgamma Mono maintains the therapeutic effect among the patients with DSPN after 2 months of reception.